Skip to content

Nuvalent, Inc. NUVL Earnings yield

Earnings yield at other companies

Pfizer logo
PfizerPFE
6.8%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-10.8%-2.6pp
Summit Therapeutics logo
Summit TherapeuticsSMMT
-8.2%-11.1pp
Exelixis logo
ExelixisEXEL
7.4%+1.1pp
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-7.1%-1.8pp
Incyte logo
IncyteINCY
7.6%+7.5pp

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Calculated from Nuvalent, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s earnings yield?
Nuvalent, Inc. (NUVL) reported earnings yield of -5.6% in Q1 2026.
How has Nuvalent, Inc.'s earnings yield changed year-over-year?
Nuvalent, Inc.'s earnings yield increased by 5.7% year-over-year, from -5.9% to -5.6%.
What is the long-term trend for Nuvalent, Inc.'s earnings yield?
Over 4 years (2021 to 2025), Nuvalent, Inc.'s earnings yield has grown at a 2.0% compound annual growth rate (CAGR), from -5% to -5.4%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.